Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

19.33 -3.69 (-16.03%)
Official Closing Price Updated: 7:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
News headline image
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit ↗
Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny. 
Via The Motley Fool
Topics Artificial Intelligence Lawsuit Stocks
News headline image
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin ↗
Via Chartmill
Dow Futures Push Higher After Breaking 50,000: Why OPGN, ACHR, LI, HIMS, CING Are Trending Today ↗
Via Stocktwits
Topics Stocks
HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗
Via Stocktwits
News headline image
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗
These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue. 
Via The Motley Fool
Topics Intellectual Property
Which stocks are most active on Monday? ↗
Via Chartmill
News headline image
Why Novo Nordisk Stock Just Popped ↗
Novo Nordisk is suing Hims & Hers -- but Hims & Hers already surrendered. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Why Hims & Hers Stock Just Got Destroyed ↗
Everyone's ganging up on Hims & Hers stock this week. 
Via The Motley Fool
Topics Lawsuit
News headline image
Why Hims & Hers Health (HIMS) Stock Is Nosediving
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 23.6% in the morning session after the company stopped offering its copycat version of Novo Nordisk's popular weight-loss drug, Wegovy,... 
Via StockStory
Topics Intellectual Property Lawsuit
News headline image
The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash
The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗
According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy. 
Via Stocktwits
Topics Lawsuit
News headline image
Why Eli Lilly Stock Just Popped ↗
Novo Nordisk just did Eli Lilly stock a huge favor. 
Via The Motley Fool
Topics Lawsuit
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn
The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of... 
Via MarketMinute
Topics Earnings Intellectual Property
News headline image
The GLP-1 Reckoning: Why Hims & Hers (HIMS) Pivoted and Shed 20% of Its Value
On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently... 
Via Finterra
Topics Earnings Economy Intellectual Property
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗
Novo stated that it has filed the lawsuit to protect its intellectual property and the American public. 
Via Stocktwits
Topics Intellectual Property Lawsuit
Dow 50,000: A Milestone for the History Books Amidst an AI Spending War ↗
Via Chartmill
Topics Artificial Intelligence Stocks
News headline image
HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗
Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight. 
Via Stocktwits
Topics Intellectual Property Law Enforcement
News headline image
A Billion-Dollar Kickoff: Super Bowl LX Prediction Markets Hit Record $1B in Trading Volume
As the Seattle Seahawks and New England Patriots prepare to take the field for Super Bowl LX at Levi’s Stadium, the real action is happening on digital ledger boards and order books. In a historic... 
Via PredictStreet
Topics Derivatives
News headline image
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗
Via MarketBeat
News headline image
HIMS Stock Slumps After-Hours On Regulatory Scrutiny On Heels Of Compounded Wegovy Pill Launch ↗
The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs. 
Via Stocktwits
News headline image
The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market
The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Why Shares of Novo Nordisk Stock Collapsed This Week ↗
The drugmaker is facing pricing pressures on its weight loss medications. 
Via The Motley Fool
News headline image
Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗
The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs. 
Via Stocktwits
Topics Fraud Law Enforcement
News headline image
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗
There's another fight brewing around GLP-1 drugs -- this time on the delivery side. 
Via The Motley Fool
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.